A. Positions and Honors.
|
|
- Darren Chandler
- 6 years ago
- Views:
Transcription
1 BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME Eron, Joseph J., Jr. era COMMONS USER NAME POSITION TITLE Associate Professor of Medicine EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) INSTITUTION AND LOCATION DEGREE (if applicable) YEAR(s) FIELD OF STUDY State University of New York, Binghamton, NY B.S Biochemistry Harvard Medical School, Boston, MA M.D Medicine Harvard Medical School, Boston, MA Residencey Internal Medicine Harvard Medical School, Boston, MA Fellowship Infectious Diseases A. Positions and Honors. Employment Director of Internal Medicine, Zuni Indian Health Service Hospital, Zuni, New Mexico Assistant Professor of Medicine, School of Medicine, Infectious Diseases, UNC-CH Associate Professor of Medicine, School of Medicine, Infectious Diseases, UNC-CH 2005-Present Professor of Medicine, School of Medicine, Infectious Diseases, UNC-CH Other Experiences and Professional Memberships: Director of Clinic, Division of Infectious Diseases, UNC-CH Co-Principal Investigator, AIDS Clinical Research Group, UNC-CH Member, ACTG Phase I - II Primary Infection Working Group, ACTG, NIAID Member, HIV Disease Research Agenda Committee, AIDS Clinical Trials Group, NIAID 1995-Present Associate Director, General Clinical Research Unit, UNC-CH 1998-Present Director, Clinical Core, UNC Center for AIDS Research, UNC-CH 2001-Present Principle Investigator AIDS Clinical Research Group, UNC-CH 2001-Present Member, HIV Disease Research Agenda Committee, AIDS Clinical Trials Group, NIAID Vice Chair, HIV Research Advisory Committee, AIDS Clinical Trials Group, NIAID 2002-Present Chair, Data Safety Monitoring Board, TMC-125 Protocol, AIDS Clinical Trials Group, NIAID 2004-Present Chair, HIV Research Advisory Committee, AIDS Clinical Trials Group, NIAID 2004-Present Member, Scientific Agenda Steering Committee, AIDS Clinical Trials Group, NIAID 2006-Present Chairperson of the AIDS Research Review Committee (AIDSRRC), NIAID Honors and Awards: 1994 Medicine Housestaff Teaching Award at University of North Carolina, Chapel Hill 1995 UNC-CH Junior Faculty Development Award, 2000 Alpha Omega Alpha, Medical Honor Society, (nominated by UNC Medical Students) 2005 UNC-CH Distinguished Teaching Award for Post-Baccalaureate Instruction B. Selected peer-reviewed publications (in chronological order). Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr May;42(1): Thompson MA, Kessler HA, Eron JJ, Jacobson JM, Adda N, Shen G, Zong J, Harris J, Moxham C, Rousseau FS and DAPD-101 Study Group. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 2005, 19: PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Biographical Sketch Format Page
2 Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al, for the AIDS Clinical Trials Group (ACTG) 398 Study Team. Dual vs. Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial. JAMA 288(2) 2002: Pilcher CD, McPherson JT, Leone PA, Smurzynski M, et al, Eron JJ, et al. Real-Time, Universal Screening for Acute HIV Infection in a Routine HIV Counseling and Testing Population. JAMA 288(2) 2002: Garba ML, Pilcher CD, Bingham AL, Eron JJ, Frelinger JA. HIV Antigens Can Induce TGF-Beta (1)-Producing Immunoregulatory CD8+ T Cells. J Immunol 168(5) 2002: Freel SA, Fiscus SA, Pilcher CD, et al, Eron JJ, et al. Envelope Diversity, Coreceptor Usage, and Syncytium- Inducing Phenotype of HIV-1 Variants in Saliva and Blood During Primary Infection. AIDS 17(14)2003: Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, et al. A Phase II Clinical Study of the Long-Term Safety and Antiviral Activity of Enfuvirtide-Based Antiretroviral Therapy. AIDS 17(5) 2003: Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41- Mediated Virus Fusion, in HIV Infected Adults. AIDS Res Hum Retroviruses 19(1) 2003: 83. Lalezari JP, Henry K, O Hearn M, Montaner JS, Piliero PJ, et al, Eron JJ, et al. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. NEJM 348(22) 2003: Kilby JM, Eron JJ Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 3487(22)2003: Fischl MA, Ribaudo HJ, Collier AC, Erice A, et al, Eron JJ, et al, for the AIDS Clinical Trials Group 388 Study Team. A Randomized Trial of Two Different Four-Drug Antiretroviral Regimens vs. a Three-Drug Regimen in Advanced Human Immunodeficiency Virus Disease. J Infect Dis 188(5) 2003: Weintrob AC, Giner J, Menezes P, et al, Eron JJ, et al. Infrequent Diagnosis of Primary HIV Infection: Missed Opportunities in Acute Care Settings. Arch Intern Med 163(17) 2003: Gulick RM, Meibohm A, Havlir D, Eron JJ, et al. Six-Year Follow-up of HIV-1-Infected Adults in a Clinical Trial of Antiretroviral Therapy With Indinavir, Zidovudine, and Lamivudine. AIDS 17(16) 2003: Hammer SM, Bassett R, Squires KE, Fischl MA, et al, Eron JJ, et al, for the ACTG 372B/D Study Team. A Randomized Trial of Nelfinavir and Abacavir in Combination With Efavirenz and Adefovir Dipivoxil in HIV-1 Infected Persons With Virologic Failure Receiving Indinavir. Antiviral Therapy 8(6) 2003: Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, et al, Eron JJ, et al. A Six-Week Randomised Controlled Trial to Compare the Tolerability, Pharmacokinetics, and Antiviral Activity of GW and Amprenavir in HIV-1-Infected Patients. Antimicrob Agents Chemother 2004 Jan;48(1): Pilcher CD, Price MA, Hoffman IF, Martinson FE, Kazembe PN, Eron JJ, et al. Frequent Detection of Acute Primary HIV Infection in Men in Malawi. AIDS Feb 20;18(3): Hicks CB, King MS, Gulick RM, White AC, Eron JJ, et al. Long-Term Safety & Durable Antiretroviral Activity of Lopinavir/Ritonavir in Treatment-Naïve Patients: Four-Year Follow-up Study M AIDS ;18(5): Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest Apr;113(7): Conradie F, Sanne IM, Venter WD, Eron JJ. Failure of Lopinavir-Ritonavir (Kaletra) Containing Regimen in an Antiretroviral Naïve Patient. AIDS 2004 Apr 30;18(7): Pilcher CD, Tien CH, Eron JJ, Vernazza PL, Leu SY, et al, the QUEST Primary HIV Infection Study Group. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis ;189(10): Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, et al. Once-Daily vs. Twice- Daily Lopinavir/Ritonavir in Antiretroviral-Naïve HIV+ Patients: 48-Week Follow-up. J Infect Dis 189(2) 2004: Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, et al. Short-Term Safety and Antiretroviral Activity of T-1249, a Second-Generation Fusion Inhibitor of HIV. J Infect Dis : Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. The Pharmacokinetics, Safety, and Initial Virologic Response of a Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir. JAIDS 2004 Aug 1;36(4): Lim ML, Min SS, Eron JJ, Bertz R, Robinson M, et al. Co-Administration of Lopinavir/Ritonavir and Phenytoin Results in a Two-way Drug Interaction Through Cytochrome P-450 Induction.JAIDS 36(5) 2004: Wood R, Eron JJ, Arasteh K, Teofilo E, Trepo C, et al A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir + Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients Brief Clin Infect Dis 39(4) 2004: 591-4
3 Frank I, Bosch R, Fiscus SA, Valentine F, et al, Eron JJ, for the ACTG 307 Study Team. Activity, Safety, and Immunologic Effects of Hydroxyurea 1000 mg and 1500 mg Added to Didanosine in Antiretroviral Naïve and Experienced HIV-1 Infected Subjects. AIDS Res Hum Retroviruses 2004 ; 20(9): Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, et al, Eron JJ. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type1. JVirol Oct;78(20): Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, et al.; for the Adult AIDS Clinical Trials Group 5055 Protocol Team. Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV- Infected Individuals. J AIDS 2004 Nov 1;37(3): Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, et al. Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation. JAIDS 2004 Dec 15;37(5): C. Research Support Federally Supported Research Projects 5 M01 RR Orringer (PI) 12/01/02-11/30/07 General Clinical Research Center Associate Director To serve as an institutional resource where health professionals of all types can receive training to conduct clinical research, to facilitate the rapid translation of advances in basic scientific knowledge into new or improved methods for patient care, and to provide a facility where the cause and the natural history of human illness can be defined and where disease progression, prevention, control, and cure can be studied. 3-U01-AI S2 Eron (PI) 04/01/05-12/31/06 /NIAID UNC Aids Clinical Trials Unit Co-P.I , P.I Present Originally Funded 09/01/87 The major goals of this project are to provide an effective and efficient system to evaluate the safety and efficacy of the therapeutic interventions against HIV infection, AIDS, and its associated conditions. 5 P30 AI Swanstrom (PI) 06/01/06-05/31/11 /NIAID Center for AIDS Research (CFAR) Clinical Core Director Facilitate and coordinate HIV translational research for basic scientists and clinical investigators. The Clinical Core promotes the development of new areas of HIV research by supporting new and experienced investigators. 5 U01 AI Haynes, PI 10/01/05-006/30/12 Center for HIV/AIDS Vaccine Initiative (CHAVI) Subcontract with Duke University, prime grantee. UNC will participate in a multi-center effort to develop new HIV vaccine strategy. UNC faculty in Lilongwe, Malawi, and on the UNC campus will conduct clinical observational studies designed to detect patients with acute HIV infection and to enroll such subjects in an observational cohort (Domestic Unit of Core B). UO1 AI41530 Pilcher, site PI 7/01/05-06/30/07 NIAID/ AIEDRP This subcontract to UAB s AIEDRP main grant (Kilby, PI) will support the recruitment and retention of acutely HIV infected patients to AIEDRP-funded research studies
4 AACTG.45.IICTU.07 Eron, PI 12/01/02-12/31/06 Social and Scientific Systems International Adult AIDS Clinical Trials Unit-Technical Assistance Project Technical assistance and capacity building project for the conduct of Adult AIDS Clinical Trials Group studies A5175, A5208 and A5199 in Lilongwe, Malawi. Pending RO1 Ahuja (PI) 12/01/06 11/30/11 Chemokine Systems and Prognosis in HIV Disease and Outcome of Therapy A pending application. Using the AACTG ALLRT cohort (HIV-1 infected individuals enrolled in a longitudinal observational study on HAART era) to probe the relationship between host genotype and prognosis of HIV-1 disease and outcome to antiretroviral therapies. Non-Federally Sponsored Research Projects PA Eron (PI) 11/01/04-10/31/06 Panacos Pharmaceuticals Phase IIA Proof of Principle Study evaluating antiretroviral activity of a novel assembly inhibitor. GSK ESS (KLEAN) Eron (PI) 02/24/04-02/23/06 (Ongoing) GlaxoSmithKline GW433908, Combivir, Epivir, ABC/3TC, Kaletra, RTV Phase III Study comparing fos-amprenavir / lopinavir / ritonavir both given with abacavir / lamivudine in HIV+ treatment naïve subjects. 03-MED-322 Eron (PI) 3/01/04-3/01/06 Boehringer-Ingelheim BI Tipranavir Open Label Tipranavir + Ritonavir Trimeris Pharmaceuticals Protocol T Eron (PI) 03/10/99-Ongoing A Phase 2 Evaluation of The Safety, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults by Subcutaneous Injection in Combination with Oral Antiretrovirals. Protocol T Eron (PI) 03/10/99-Ongoing A Rollover Study of T-20 Administered in Combination with a Background Antiviral regimen in HIV-1 Positive Adults Who Have Completed Clinical Trial T Protocol T Eron (PI) 02/09/01-5/31/05 (Ongoing) Phase III clinical trail with comparing T20-301/Ro in combination with OB therapy (based on the patient s prior history and genotypic/phenotypic resistance testing), to the OB therapy alone, in patients who have failed the currently available classes of antiretrovirals. Protocol M Eron (PI) 11/19/02-03/01/06 Abbott Laboratories, Inc. LPV/r + INV v LPV/r + Combivir Completed Non-Federally Sponsored Research Projects Abbott Laboratories, Inc. Protocol M Eron (PI) 12/19/02-12/18/04 A Phase I/II Study of ABT-378/Ritonavir in Combination with Reverse Transcriptase Inhibitors in ARV Naïve HIV+ Patients. Protocol M Eron (PI) 01/05/01 01/04/04
5 Safety, tolerability and pharmacokinetics of high dose ABT-378/r and ABT-378/r with ritonavir. Antiretroviral activity ABT-378/r and ABT-378/r with ritonavir. Protocol 035 Eron (PI) 05/01/95 06/30/04 Merck Research Laboratories A Multicenter, Double-Blind, Randomized, One-Year Study to Evaluate the Safety and Activity of MK-639 Administered in Combination With Zidovudine and 3TC Versus Zidovudine and 3TC Versus MK-639 Monotherapy for the Treatment of HIV Infection. 2 P01 AI Johnston (PI) 09/28/01-06/30/06 Therapeutic Vaccination for HIV Using VEE Vectors Co-Primary Investigator The program project will initially design, construct and produce a VEE vectored HIV clade B vaccine to be used in a therapeutic Phase I/II trial in HIV-infected HAART-treated individuals. Concurrently, the Program will develop improved therapeutic vaccine modalities for subsequent trial in humans.
The US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationA new approach for 'deep salvage' trials in advanced HIV infection [OPINION]
A new approach for 'deep salvage' trials in advanced HIV infection [OPINION] AIDS:Volume 21(12)31 July 2007p 1503-1506 Lederman, Michael Ma; Miller, Veronicab; Weller, Ianc; Deeks, Steven Gd >From the
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationPatients with persistently low CD4 counts on antiretroviral
Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationFrançois Raffi, 1 Christine Katlama, 2 Michael Saag, 3 Martin Wilkinson, 6 Jain Chung, 5 Lynn Smiley, 4 and Miklos Salgo 5
HIV/AIDS MAJOR ARTICLE Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO)
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 30 Dec 2018 00:34:16 GMT) CTRI Number CTRI/2009/091/000652 [Registered on: 27/10/2009] - Last Modified On 11/03/2014 Post Graduate Thesis Type of Trial
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationPerspective Current Concepts in Antiretroviral Therapy Failure
International AIDS Society USA Perspective Current Concepts in Antiretroviral Therapy Failure Currently, the goal for the first and second, and possibly the third, antiretroviral regimen is the suppression
More informationRecommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Recommendations for Use of Antiretroviral s in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004, CDC and updated
More informationOnce-a-Day Highly Active Antiretroviral Therapy: A Systematic Review
HIV/AIDS MAJOR ARTICLE Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review Javier Ena and Francisco Pasquau HIV Unit, Department of Internal Medicine, Marina Baixa Hospital, Villajoyosa,
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationAdvances in Antiretroviral Therapy
Advances in Antiretroviral Therapy Mary A. Albrecht, MD, Timothy J. Wilkin, MD, Eoin P. G. Coakley, MD, and Scott M. Hammer, MD As witnessed in previous years, antiretroviral therapy was a dominant theme
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationTreatment options for antiretroviral-experienced
New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary
More informationReport on New Patented Drugs - Fuzeon
Report on New Patented Drugs - Fuzeon October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationMechanisms of rifamycin-antiretroviral drug interactions
Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors Two previously published
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationDrug-Drug Interactions and the Pharmacotherapy of HIV Infection
International AIDS Society USA Topics in HIV Medicine Perspective Drug-Drug Interactions and the Pharmacotherapy of HIV Infection Angela D. M. Kashuba, PharmD Knowledge of drug-drug interactions is crucial
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationInternational Journal of Pharma and Bio Sciences V1(2)2010 A STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS.
SANKAR VEINTRAMUTHU 1 *, RUCKMANI KANDASAMY 2, VELAYUTHAM KANNIYAPPAN 1, NITHYANANTH MUNUSAMY 1 1 Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore- 641004. 2 Department of Pharmaceutical
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationAWMSG Secretariat Assessment Report Advice no Darunavir (Prezista
AWMSG Secretariat Assessment Report Advice no. 0311 Darunavir (Prezista ) for the treatment of HIV-1 infection in treatment-experienced children and adolescents This assessment report is based on evidence
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationVirologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 17, Number 3, 2001, pp. 203 210 Mary Ann Liebert, Inc. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationPrema Menezes. Chapel Hill Approved by: William C. Miller, MD, MPH, PhD. Adaora A. Adimora, MD, MPH. Joseph J. Eron Jr, MD. Peter A.
Is there a trial effect in HIV clinical trials? Identifying who participates in clinical trials And assessing the effect of trial participation on the response to highly active antiretroviral therapy Prema
More informationHPTN 052. Myron S. Cohen, MD Principal Investigator. Presented at the 6 th Int. Workshop on HIV Transmission, July 2011, Rome, Italy
HPTN 052 Myron S. Cohen, MD Principal Investigator Presented at the 6 th Int. Workshop on HIV Transmission, 14 15 July 2011, Rome, Italy Antiviral Treatment as Prevention Extensive biological plausibility
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationUPDATE. New antiretroviral drugs R. M. Gulick
UPDATE New antiretroviral drugs R. M. Gulick Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York,
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationcontinuous viral replication. increased viral resistance. development of clinical complications. reduced survival.
Optimizing Adherence to Highly Active Antiretroviral Therapy: A Focus on Fosamprenavir Nathaniel Eraikhuemen, PharmD, Natalie Perry, PharmD, Evans Branch III, PharmD, Daryl Norwood, PharmD, and Marlon
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationProtease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore
Protease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore Reprinted from The prn Notebook march 2004 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAntiviral Therapy 2013; 18: (doi: /IMP2436)
Antiviral Therapy 2013; 18:345 354 (doi: 10.3851/IMP2436) Original article Decreasing rate of multiple treatment modifications among individuals who initiated antiretroviral therapy in 1997 2009 in the
More informationRapid Review Response HIV Medication and Depression
Rapid Review Response HIV Medication and Depression Question: Is depression a side effect of anti-retroviral medications taken by people living with HIV? The issue and why it s important The Ontario HIV
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationPerspective Antiretroviral Therapy: Select Lessons From Recent Studies
International AIDS Society USA Topics in HIV Medicine Perspective Antiretroviral Therapy: Select Lessons From Recent Studies Our understanding of HIV pathogenesis continues to evolve and form the foundation
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationWHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION
18th Expert Committee on the Selection and Use of Essential Medicines 1 (21 to 25 March 2011) Section 6.4.2 Antiretrovirals -- Raltegravir (Adults) WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION 1.
More informationTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Send Orders for Reprints to reprints@benthamscience.ae 38 The Open AIDS Journal, 2015, 9, 38-44 Open Access Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationDaniel J Escudero, PhD
Daniel J Escudero, PhD Postdoctoral Fellow Department of Epidemiology T.H. Chan School of Public Health Tel: (617) 432-1899 (office); (551) 404-7592 (cell) Email: Escudero@hsph.harvard.edu 1. EDUCATION
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationDespite the wealth of efficacy data from
OPTIMIZING HIV DRUG THERAPY * John G. Bartlett, MD ABSTRACT The clinical success of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus disease is one of the great
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationThe prevalence of antiretroviral drug resistance in the United States
The prevalence of antiretroviral drug resistance in the United States Douglas D. Richman a,b, Sally C. Morton c, Terri Wrin d, Nicholas Hellmann d, Sandra Berry c, Martin F. Shapiro c,e and Samuel A. Bozzette
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More information